Upadacitinib for the treatment of rheumatoid arthritis following previous basic therapy
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of upadacitinib compared with the standard treatments in people having treatment with a biologic or a JAK inhibitor for the first time.
The manufacturer provided one relevant study. The IQWiG researchers used the data on about 1,000 patients in their analysis. 651 of these patients were given upadacitinib in combination with methotrexate (MTX), and 327 participants received a combination of adalimumab and MTX.
The following results were found after half a year: